Recce Pharmaceuticals Expands Phase 3 Diabetic Foot Trial With Comparator Arm

Recce expands its Phase 3 trial, but offers no new financial or efficacy data.

What the company is saying

Recce Pharmaceuticals announces Human Research Ethics Committee approval to expand its pivotal Australian Phase 3 trial of RECCE 327 topical gel for diabetic foot infections. The company frames this as a major step, highlighting the addition of a randomised active-controlled non-inferiority arm and direct comparison with four physician-selected antibiotics. Messaging emphasizes the scale of the amended study—208 participants—and the introduction of calibrated digital wound imaging for objective measurement. The announcement stresses ongoing recruitment and dosing, as well as alignment with a parallel pivotal Phase 3 program in Indonesia, positioning this as part of a broader international regulatory strategy. Recce’s language is confident and focused on clinical progress, but does not mention financials or commercialisation. The tone is positive, with forward-looking statements about generating a comparative data package for regulatory submissions, but no claims of realised efficacy or market impact.

What the data suggests

The only concrete figures disclosed are operational: 208 participants for the amended study, four comparator antibiotics, and a planned interim analysis at 104 participants. No efficacy, safety, or financial data are provided. The announcement confirms that patient recruitment and dosing are ongoing, and that the protocol amendment is approved but not yet implemented. There is no evidence yet on whether R327G performs as well as or better than standard antibiotics, nor any data on interim or final outcomes. The disclosure is detailed on trial design but omits any metrics on cash position, R&D spend, or revenue. The lack of financial and clinical results means investors cannot gauge the likelihood of regulatory approval or commercial success. The data supports operational progress in clinical development, but does not demonstrate value creation or risk reduction.

Analysis

The announcement is generally proportionate in tone, focusing on the expansion of a pivotal Phase 3 trial and the addition of a new comparator arm, both of which are supported by specific, realised milestones (HREC approval, ongoing recruitment, protocol amendments). About half of the key claims are forward-looking, relating to future enrolment, interim analysis, and regulatory submissions, but these are standard for clinical trial updates and do not overstate progress. There is no evidence of exaggerated language or inflated claims about commercial outcomes, and no large capital outlay or immediate financial impact is disclosed. The absence of any profitability or financial metrics means the true_signal cannot exceed weak_positive, as investors cannot assess value creation. The data supports genuine operational progress in clinical development, but the announcement does not provide evidence of commercial or financial impact.

Risk flags

• ●There is no disclosed efficacy or safety data for R327G, so the risk remains high that the product may not demonstrate non-inferiority to standard antibiotics. Without clinical results, investors cannot assess the probability of trial success or regulatory approval.
• ●The absence of financial data—such as cash reserves, burn rate, or funding runway—prevents any assessment of the company’s ability to sustain operations through to trial completion and regulatory submission. This omission is material for investors evaluating dilution or insolvency risk.
• ●Operational risk is present because the protocol amendment is approved but not yet implemented, meaning timelines could slip if recruitment, randomisation, or digital imaging rollout encounter delays. The interim analysis is contingent on reaching 104 treated participants, which may take longer than anticipated.

Bottom line

This announcement signals incremental operational progress for Recce’s Phase 3 DFI trial, with regulatory approval to expand the study and add a direct comparator arm. No new clinical, safety, or financial data are disclosed, so the impact is limited to trial design rather than value creation. The absence of financial metrics leaves investors unable to assess funding risk or the likelihood of dilution. Until interim or final results are released, the company’s claims about R327G’s potential remain untested. Investors should treat this as a procedural update, not a catalyst for revaluation. The most important takeaway is that the pathway to commercialisation and regulatory approval is still unproven and dependent on future data.

Announcement summary

(ASX: RCE) Recce Pharmaceuticals has received Human Research Ethics Committee (HREC) approval to expand its pivotal Australian Phase 3 trial of RECCE 327 topical gel (R327G) for diabetic foot infections (DFI) with a new randomised active-controlled non-inferiority arm. The amended study will enrol 208 participants and compare R327G directly with one of four physician-selected antibiotics used in DFI treatment. Patient recruitment and dosing are continuing under the existing protocol while Recce prepares to implement the amendment, with mild to moderate DFI patients already participating in the study. The expanded Australian trial sits alongside Recce’s ongoing pivotal Phase 3 DFI program in Indonesia and forms part of its broader regulatory strategy across multiple international markets. An interim analysis is planned once 104 participants have been enrolled, randomised, and treated, and have either completed follow-up to the end of treatment or withdrawn prematurely. The updated protocol introduces calibrated digital wound imaging to provide standardised objective measurements alongside investigator assessment of the infection. R327G is the topical formulation of RECCE 327, one of three patented broad-spectrum synthetic polymer anti-infectives in Recce’s development pipeline, alongside RECCE 435 and RECCE 529.

Disagree with this article?